Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP

Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP

Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.

Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.

First Ascent Biomedical - For Patients

For Patients

Advanced cancer patients who have exhausted standard therapies now have a new option in highly individualized, data-driven treatment planning.

First Ascent Biomedical - For Physicians

For Physicians

Validated and published studies with leading cancer centers, oncologists can take advantage of first-in-kind treatment planning technology with average 10-day turnaround.

First Ascent Biomedical - For Industry

For Industry

Demonstrated with leading industry partners, our Drug Prediction Platform – DxPP uses causal ML platform can accelerate the drug development pipeline for all types of cancer.

First Ascent Biomedical - For Patients

For Patients

Advanced cancer patients who have exhausted standard therapies now have a new option in highly individualized, data-driven treatment planning.

First Ascent Biomedical - For Physicians

For Physicians

Validated and published studies with leading cancer centers, oncologists can take advantage of first-in-kind treatment planning technology with average 10-day turnaround.

First Ascent Biomedical - For Industry

For Industry

Demonstrated with leading industry partners, our drug sensitivity testing and causal ML platform can accelerate the drug development pipeline for all types of cancer.

First Ascent Biomedical - For Patients

For Patients

Advanced cancer patients who have exhausted standard therapies now have a new option in highly individualized, data-driven treatment planning.

First Ascent Biomedical - For Physicians

For Physicians

Validated and published studies with leading cancer centers, oncologists can take advantage of first-in-kind treatment planning technology with average 10-day turnaround.

First Ascent Biomedical - For Industry

For Industry

Demonstrated with leading industry partners, our drug sensitivity testing and causal ML platform can accelerate the drug development pipeline for all types of cancer.

First Ascent’s Ex Vivo Drug Response Identification & Validation Engine – xDRIVE Platform is a first-in-kind medical oncology decision support system that integrates functional drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping resulting in prioritized therapeutic solutions tailored to the patient’s tumor vulnerabilities and validated through tests run on the patient’s own cells.

Publication and Pharma Partners

The Latest First Ascent Biomedical News